Rothschild & Co Asset Management US’s Nektar Therapeutics NKTR Stock Holding History

Rothschild & Co Asset Management US’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,476	Closed	-$6.94M	–	380
2018 Q2	$6.94M	Sell	9,476 -18,067	-66%	-$20.8M	0.07%	286
2018 Q1	$43.9M	Sell	27,543 -14,276	-34%	-$18.4M	0.49%	56
2017 Q4	$37.5M	Sell	41,819 -37,009	-47%	-$21.9M	0.4%	93
2017 Q3	$28.4M	Buy	78,828 +3,778	+5%	+$1.18M	0.31%	132
2017 Q2	$22M	Buy	75,050 +1,620	+2%	+$468K	0.25%	162
2017 Q1	$25.9M	Buy	73,430 +1,533	+2%	+$345K	0.3%	126
2016 Q4	$13.2M	Buy	71,897 +69,942	+3,578%	+$14.2M	0.17%	212
2016 Q3	$504K	Buy	1,955 +49	+3%	+$12.6K	0.01%	444
2016 Q2	$407K	Buy	+1,906	New	+$426K	0.01%	479

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Rothschild & Co Asset Management US's NKTR Position: Q3 2018 in Review

Rothschild & Co Asset Management US sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 9,476 shares — an estimated $6.94M sold.

Rothschild & Co Asset Management US first reported a position in NKTR in Q2 2016 and held it in 9 quarters. The position peaked at $43.9M in Q1 2018. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

Rothschild & Co Asset Management US reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
Rothschild & Co Asset Management US sold 9,476 Nektar Therapeutics shares in Q3 2018, an estimated $6.94M.
Rothschild & Co Asset Management US first reported a position in Nektar Therapeutics in Q2 2016 and held it in 9 quarters.
Rothschild & Co Asset Management US's Nektar Therapeutics position peaked at $43.9M in Q1 2018.
389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2018, filed 13 Nov 2018.